Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Pharm Des ; 23(20): 2976-2990, 2017.
Article in English | MEDLINE | ID: mdl-28215159

ABSTRACT

The artificial nanostructures such as nanoparticles and natural nanostructures such as secreted nanosized extracellular vesicles known as exosomes are promising tools for the realization of personalized medicine. Radionanomedicine is a recently coined term for the simultaneous application of either radiation technology or nuclear medicine with nanomedicine. In addition, radioexosomics is our suggested term for the study of exosomes functions, cytotoxicity, cancerogenicity, and biodistribution using radiation technology and nuclear medicine tracing technology. Prostate cancer (PCa) is the most commonly diagnosed cancer in males and a big majority of patients with PC progress to castration-resistant prostate cancer (CRPC) mostly. The mechanisms leading to development of CRPC remain poorly understood and there is still a need to improve the therapeutic options available for PCa. In this review, a wide variety of nanostructure-based prostate cancer research using radiation technology and nuclear medicine is discussed. In addition, we will present what is currently known about the function of exosomes in PCa. The review concludes by summarizing the current status and future perspectives of radionanomedicine and radioexosomics for understanding PCa biology, as well as PCa enhancement of targeting strategies, drug delivery, molecular imaging and therapy.


Subject(s)
Drug Delivery Systems , Exosomes/metabolism , Nanoparticles/chemistry , Prostatic Neoplasms/drug therapy , Radiopharmaceuticals/administration & dosage , Humans , Male , Radiopharmaceuticals/chemistry , Tissue Distribution
2.
J Clin Pharmacol ; 48(12): 1430-7, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18832293

ABSTRACT

This study aimed to investigate the bioequivalence of a test formulation of tibolone with the marketed reference formulation in 24 young healthy female volunteers. Tibolone is a synthetic steroid hormone for menopausal women. Volunteers were treated with the 2 formulations of tibolone (total dose of active ingredient 2.5 mg) according to a 2 x 2 crossover design with a 1-week washout period. Plasma concentrations of 3alpha- and 3beta-hydroxytibolone, which are major metabolites of tibolone, were assayed in timed samples over a 24-hour period with a validated gas chromatography/mass spectrometry (GC/MS) method that had a lower limit of quantification of 0.5 ng/mL. The reference and test formulations gave a mean 3alpha-hydroxytibolone C(max) of 5.0 and 5.2 ng/mL, respectively, and a mean 3beta-hydroxytibolone C(max) of 16.4 and 16.5 ng/mL, respectively. The mean AUC(t) of 3alpha-hydroxytibolone was 24.7 and 24.3 ng h/mL, whereas the mean AUC(t) of 3beta-hydroxytibolone was 57.6 and 54.8 ng h/mL for the test and reference formulations, respectively. The authors did not find significant differences in pharmacokinetic parameters between the 2 formulations, but metabolite formation was different from reports in postmenopausal women. The authors therefore measured the effects of estradiol on the expression of the tibolone-metabolizing enzymes, from the aldo-keto reductase (AKR1C) family, using HepG2 cell (human hepatoma cells) and MCF-7 cell (human breast cancer cells). Estradiol increased mRNA levels of AKR1C1, AKR1C2, and AKR1C3 and protein levels of total AKR1C in HepG2 cells. Estradiol selectively enhanced levels of AKR1C2 mRNA in MCF-7 cells. Thus, changes in the major metabolites of tibolone might result from changes in AKR1C family expression by patient estrogen status.


Subject(s)
Alcohol Oxidoreductases/metabolism , Estradiol/pharmacology , Norpregnenes/pharmacokinetics , Premenopause/metabolism , 20-Hydroxysteroid Dehydrogenases/genetics , 20-Hydroxysteroid Dehydrogenases/metabolism , 3-Hydroxysteroid Dehydrogenases/genetics , 3-Hydroxysteroid Dehydrogenases/metabolism , Adult , Alcohol Oxidoreductases/genetics , Aldehyde Reductase , Aldo-Keto Reductase Family 1 Member C3 , Aldo-Keto Reductases , Area Under Curve , Cell Line, Tumor , Cross-Over Studies , Enzyme Activation/drug effects , Estrogen Receptor Modulators/metabolism , Estrogen Receptor Modulators/pharmacokinetics , Estrogen Receptor Modulators/pharmacology , Female , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/genetics , Glucose Transporter Type 1/genetics , Glucose Transporter Type 1/metabolism , Half-Life , Humans , Hydroxyprostaglandin Dehydrogenases/genetics , Hydroxyprostaglandin Dehydrogenases/metabolism , Hydroxysteroid Dehydrogenases/genetics , Hydroxysteroid Dehydrogenases/metabolism , Immunoblotting , Norpregnenes/blood , Norpregnenes/metabolism , Norpregnenes/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Therapeutic Equivalency , Young Adult
3.
Biochem Pharmacol ; 72(7): 850-9, 2006 Sep 28.
Article in English | MEDLINE | ID: mdl-16890209

ABSTRACT

Toll-like receptors (TLRs) play an important role in recognition of microbial components and induction of innate immunity. The microbial components trigger the activation of two downstream signaling pathways of TLRs; MyD88- and/or TRIF-dependent pathways leading to activation of NF-kappaB. (-)-Epigallocatechin-3-gallate (EGCG), a flavonoid found in green tea, is known to inhibit NF-kappaB activation induced by many pro-inflammatory stimuli. EGCG was shown to inhibit the activity of IKKbeta which is the key kinase in the canonical pathway for NF-kappaB activation in MyD88-dependent pathway of TLRs. However, it is not known whether EGCG inhibits TRIF-dependent pathway through which more than 70% of lipopolysaccharide (LPS)-induced genes are regulated. Therefore, we attempted to identify the molecular target of EGCG in TRIF-dependent pathways of TLR3 and TLR4. EGCG inhibited the activation of IFN regulatory factor 3 (IRF3) induced by LPS, poly[I:C], or the overexpression of TRIF. The inhibition of IRF3 activation by EGCG was mediated through the suppression of the kinase activity of TBK1. However, EGCG did not inhibit activation of IRF3 induced by overexpression of constitutively active IRF3. These results suggest that the molecular target of EGCG is TBK1 in TRIF-dependent signaling pathways of TLR3 and TLR4. Therefore, our results suggest that green tea flavonoids can modulate both MyD88- and TRIF-dependent signaling pathways of TLRs and subsequent inflammatory target gene expression.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Adaptor Proteins, Vesicular Transport/physiology , Catechin/analogs & derivatives , Signal Transduction/drug effects , Toll-Like Receptors/physiology , Animals , Catechin/chemistry , Catechin/pharmacology , Cell Line , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Flavonoids/chemistry , Flavonoids/pharmacology , Gene Expression/genetics , Humans , I-kappa B Kinase/metabolism , Interferon-gamma/genetics , Luciferases/genetics , Luciferases/metabolism , Mice , Myeloid Differentiation Factor 88 , NF-kappa B/genetics , NF-kappa B/metabolism , Phenols/chemistry , Phenols/pharmacology , Polyphenols , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/physiology , Tea/chemistry , Toll-Like Receptor 2/physiology , Toll-Like Receptor 4/physiology , Transfection , NF-kappaB-Inducing Kinase
SELECTION OF CITATIONS
SEARCH DETAIL
...